PATENT CLAIM ANALYSIS

Application Number: 15867195
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-12
Patent Classification: ["540", "496000"]

Abstract:
A compound of formula I: wherein Y is selected from a single bond, and a group of formulae A1 or A2: where N shows where the group binds to the N10 of the PBD moiety.

Claim (Index 61):
The method according to  claim 59  wherein the antibody or antibody fragment is an antibody which binds to one or more tumor-associated antigens or cell-surface receptors selected from (1)-(53):\n (1) BMPR1B (bone morphogenetic protein receptor-type IB); \n (2) E16 (LAT1, SLC7A5), \n (3) STEAP1 (six transmembrane epithelial antigen of prostate); \n (4) 0772P (CA125, MUC16), \n (5) MPF (MPF, MSLN, SMR, megakaryocyte potentiating factor, mesothelin); \n (6) Napi3b (NAPI-3B, NPTIlb, SLC34A2, solute carrier family 34 (sodium phosphate), member 2, type II sodium-dependent phosphate transporter 3b), \n (7) Sema 5b (FLJ10372, KIAA1445, Mm.42015, SEMA5B, SEMAG, Semaphorin 5b Hlog, sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B); \n (8) PSCA hlg (2700050C12Rik, C530008016Rik, RIKEN cDNA2700050C12, RIKEN cDNA 2700050012 gene); \n (9) ETBR (Endothelin type B receptor); \n (10) MSG783 (RNF124, hypothetical protein FLJ20315); \n (11) STEAP2 (HGNC_8639, IPCA-1, PCANAP1, STAMP1, STEAP2, STMP, prostate cancer associated gene 1, prostate cancer associated protein 1, six transmembrane epithelial antigen of prostate 2, six transmembrane prostate protein); \n (12) TrpM4 (BR22450, FLJ20041, TRPM4, TRPM4B, transient receptor potential cation channel, subfamily M, member 4); \n (13) CRIPTO (CR, CR1, CRGF, CRIPTO, TDGF1, teratocarcinoma-derived growth factor); \n (14) CD21 (CR2 (Complement receptor 2) or C3DR (C3d/Epstein Barr virus receptor) or Hs 73792); \n (15) CD79b (CD79B, CD796, IGb (immunoglobulin-associated beta), B29); \n (16) FcRH2 (IFGP4, IRTA4, SPAP1A (SH2 domain containing phosphatase anchor protein 1a), SPAP1B, SPAP1C), \n (17) HER2; \n (18) NCA; \n (19) MDP; \n (20) IL20R\u03b1, \n (21) Brevican; \n (22) EphB2R; \n (23) ASLG659, \n (24) PSCA; \n (25) GEDA; \n (26) BAFF-R (B cell -activating factor receptor, BLyS receptor 3, BR3); \n (27) CD22 (B-cell receptor CD22-B isoform); \n (28) CD79a (CD79A, CD79\u03b1, immunoglobulin-associated alpha); \n (29) CXCR5 (Burkitt's lymphoma receptor 1); \n (30) HLA-DOB (Beta subunit of MHC class II molecule (la antigen)); \n (31) P2X5 (Purinergic receptor P2X ligand-gated ion channel 5); \n (32) CD72 (B-cell differentiation antigen CD72, Lyb-2); \n (33) LY64 (Lymphocyte antigen 64 (RP105), type I membrane protein of the leucine rich repeat (LRR) family); \n (34) FcRH1 (Fe receptor-like protein 1); \n (35) IRTA2 (Immunoglobulin superfamily receptor translocation associated 2); and \n (36) TENB2 (putative transmembrane proteoglycan) \n (37) PMEL17 (silver homolog; SILV; D12S53E; PMEL17; SI; SIL); \n (38) TMEFF1 (transmembrane protein with EGF-like and two follistatin-like domains \u00b71; Tomoregulin-1); \n (39) GDNF-Ra1 (GDNF family receptor alpha 1; GFRA1; GDNFR; GDNFRA; RETL1; TRNR1; RET1L, GDNFR-alpha1; GFR-ALPHA-1); \n (40) Ly6E (lymphocyte antigen 6 complex, locus E; Ly67,RIG-E,SCA-2,TSA-1); \n (41) TMEM46 (shisa homolog 2 (Xenopus laevis); SHISA2), \n (42) Ly6G6D (lymphocyte antigen 6 complex, locus G6D; Ly6-D, MEGT1); \n (43) LGRS (leucine-rich repeat-containing G protein-coupled receptor 5; GPR49, GPR67); \n (44) RET (ret proto-oncogene; MEN2A; HSCR1; MEN213, MTC1; PTC; CDHF12; Hs.168114; RET51, RET-ELE1); \n (45) LY6K (lymphocyte antigen 6 complex, locus K; L Y6K; HSJ001348, FLJ35226); (46) GPR19 (G protein-coupled receptor 19; Mm.4787); \n (47) GPR54 (KISS1 receptor; KISS1R, GPR54, HOT7T175, AXOR12); \n (48) ASPHD1 (aspartate beta-hydroxylase domain containing 1; LOC253982), \n (49) Tyrosinase (TYR; OCAIA; OCA1A; tyrosinase; SHEP3); \n (50) TMEM118 (ring finger protein, transmembrane 2; RNFT2; FLJ14627), \n (51) GPR172A (G protein-coupled receptor 172A; GPCR41; FLJ11856, D15Ertd747e); \n (52) CD33, and \n (53) CLL-1.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 86.0
- Lexical Diversity: 1.25806
- Patent Class: 540.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14774535', '14851348', '15510345', '11233258', '14851206']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6871581398285437
- 35 USC 102 Novelty (BERT): 0.5233011296002922
- Combined Prediction Score: 0.6707724388057186
- Mean Citation Score: 290.157776
- Max Citation Score: 330.12344
- Similarity Product: 309.36195942939764

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test